Ignite Creation Date:
2024-05-06 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03137693
Status:
TERMINATED
Last Update Posted:
2023-02-23
First Post:
2017-04-28
Brief Title:
Preoperative Stereotactic Ablative Body Radiotherapy SABR for Early-Stage Breast Cancer
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy SABR for Early-Stage Breast Cancer Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy
Status:
TERMINATED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
no responderslack of efficacy
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study involves a course of radiation to the tumor that is delivered BEFORE surgery The type of radiation is called stereotactic ablative body radiation therapy SABR The purpose of this study is to evaluate the effects good andor bad of pre-operative SABR specifically focusing on its ability to reduce the chances that additional breast surgery will be needed reducing the amount of breastheartlung tissue that is irradiated and to study the tumor-tissue effects of SABR The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment BCT is to receive radiotherapy AFTER surgery targeting either the whole breast or part of the breast
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None